Advertisement

Journal of Neuro-Oncology

, Volume 33, Issue 1–2, pp 163–169 | Cite as

In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue

  • Yutaka Mishima
  • Yoshio Imahori
  • Chihiro Honda
  • Junichi Hiratsuka
  • Satoshi Ueda
  • Tatsuo Ido
Article

Abstract

Detection and diagnosis of human malignant melanoma byPositron Emission Tomography (PET) using 18F-10B-L-BPA, a specificmelanogenesis-seeking compound synthesized for use in Boron NeutronCapture Therapy for malignant melanoma (NCT), has beendeveloped. This resulted in a novel, highly effectivemethodology for the selective three dimensional imaging ofmetastatic malignant melanomas, and for accurate determination of10B concentration in the tumor and surrounding tissue,providing almost all diagnostic information necessary for completenon-invasive radiation dose planning in the treatment ofmalignant melanoma both for NCT as well asother therapeutic modalities.

melanoma PET 18F-DOPA analogue melanoma neutron capture therapy 10B-p-boronophenyl-alanine malignant melanoma melanoma brain metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mishima Y, Shimakage T: Thermal neutron capture treatment of malignant melanoma using 10B-dopa and nB12-chlorpromazine compounds. In: Riley V (ed) Pigment Cell, vol 2, S. Karger, Basel, 1976, pp 394–406Google Scholar
  2. 2.
    Nakanishi T, Ichihashi M, Mishima Y, Matsuzawa T, Fukuda H: Thermal neutron capture therapy of malignant melanoma: in vitroradiobiological analysis. Internat J Radiat Biol 37: 573–580, 1980Google Scholar
  3. 3.
    Mishima Y, Ichihashi M, Hatta S, Honda C, Yamamura K, Nakagawa T: New thermal neutron capture therapy for malignant melanoma: melanogenesis-seeking 10B moleculemelanoma cell interaction from in vitroto first clinical trial. Pigment Cell Res 2: 226–234, 1989Google Scholar
  4. 4.
    Mishima Y, Ichihashi M, Tsuji M, Hatta S, Ueda M, Honda C, Suzuki T: Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma-seeking compound. J Invest Dermatol 92: 321S–325S, 1989Google Scholar
  5. 5.
    Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kobayashi T, Kanda K, Yoshino Y: Treatment of malignant melanoma by single neutron capture treatment with melanoma-seeking 10B-Compound. Lancet ii: 388–389, 1989Google Scholar
  6. 6.
    Kobayashi T, Hatta S, Honda C, Yamamura K, Akiyoshi T, Kanda K, Mishima Y: Estimation of absorbed doses in human malignant melanoma treated by neutron capture therapy with special references to vertical direction. Pigment Cell Res 2: 361–364, 1989Google Scholar
  7. 7.
    Ishiwata K, Ido T, Honda C, Kawamura M, Ichihashi M, Mishima Y: 4-Borono-2-[18F] fluoro-D,L-phenylalanine: a possible tracer for melanoma diagnosis with PET. Nucl Med Biol 19: 311–318, 1992Google Scholar
  8. 8.
    Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T, Honda C, Ichihashi M, Mishima Y: A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumor tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine. Melanoma Res 2: 171–179, 1992Google Scholar
  9. 9.
    Ishiwata K, Ido T, Kawamura M, Kubota K, Ichihashi M, Mishima Y: 4-Borono-2-[18F]fluoro-D-L-phenylalanine as a target compound for boron neutron capture therapy: tumor imaging potential with positron emission tomography. Nucl Med Biol 18: 745–751, 1991Google Scholar
  10. 10.
    Mishima Y: Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities-melanoma as prototype. In: Mishima Y (ed) Cancer Neutron Capture Therapy. Plenum Publ Corp, New York, 1996, pp 1–26Google Scholar
  11. 11.
    Phelps ME, Huang SC, Hoffman EJ, Kuhl DE: Validation of tomographic measurement of cerebral blood volume with C-11 labeled carboxyhemoglobin. J Nucl Med 20: 328–334, 1979Google Scholar
  12. 12.
    Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE: Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238: E69–E82, 1980Google Scholar
  13. 13.
    Patlak CS, Blasberg RG, Fenstmacher JD: Graphical evaluation of blood-to-brain transfer constants from multi-time uptake data. J Cereb Blood Flow Metabol 3: 1–7, 1983Google Scholar
  14. 14.
    Sokoloff L: Modeling metabolic processes in the brain in vivo. Ann Neurol 15(suppl.): S1–S11, 1984Google Scholar
  15. 15.
    Mishima Y: Investigation for the Extended Application of Melanoma Boron Neutron Capture Therapy. Kyoto University Research Reactor Institute–Technical Report 356: 1–305, 1991Google Scholar
  16. 16.
    Mishima Y, Ichihashi M, Honda C, Shiona M, Nakagawa T, Obara H, Shirakawa A, Hiratsuka J, Kanda K, Kobayashi T, Nozaki T, Aizawa O, Sato T, Karashima H, Yoshino K, Fukuda H: Advances in the control of human cutaneous primary and metastatic melanoma by thermal neutron capture therapy. In: Allen BJ, Moore DE, Harrington BV (eds) Progress in Neutron Capture Therapy for Cancer. Plenum Publ Corp, New York, 1992, pp 577–583Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Yutaka Mishima
    • 1
  • Yoshio Imahori
    • 2
  • Chihiro Honda
    • 3
  • Junichi Hiratsuka
    • 4
  • Satoshi Ueda
    • 2
  • Tatsuo Ido
    • 5
  1. 1.Mishima Institute for Dermatological ResearchKobe
  2. 2.Department of NeurosurgeryKyoto Prefectural UniversityKyoto
  3. 3.Department of DermatologyHyogo Pref. Kakogawa HospitalJapan
  4. 4.Department of RadiologyKawasaki Medical SchoolKurashiki
  5. 5.Cyclotron and Radioisotope CenterTohoku UniversitySendaiJapan

Personalised recommendations